To help conquer the urgent problem Australia has with melanoma and skin cancer, leading skin care brand Avène has teamed up with Melanoma and Skin Cancer Trials.

Recognising the important role clinical trials play in advancing how melanoma and skin cancer is prevented, diagnosed and treated, Avène has pledged its support by donating $1 from every Avène Sunsitive^® Sunscreen sold at Chemist Warehouse stores between 1 November and 31 December 2024.

Prominent Australian medical oncologist and Board Chair of Melanoma and Skin Cancer Trials, Prof Mark Shackleton, welcomed Avène’s support, saying it would directly impact melanoma and skin cancer patients.

“Australia has the highest rate of melanoma and skin cancer in the world, so Australians need to embrace sun safety. Sunscreen is one of the five important ways to reduce the risk of skin cancer, along with seeking shade and wearing sunglasses, sun-protective clothing, and a broad-brimmed hat,” he added.

CEO of Melanoma and Skin Cancer Trials, Gabrielle Byars, said “Avène’s donation will support our clinical trials that are improving outcomes for melanoma and skin cancer patients across Australia.”

Melanoma and Skin Cancer Trials is Australia’s only national, collaborative, independent, not-for-profit, clinical trials group focused on melanoma and skin cancer. Working with over 1,000 of the world’s best melanoma and skin cancer investigators, the group is delivering clinical trials that are advancing how doctors prevent, diagnose and treat melanoma and skin cancer.